User profiles for B. Maes
Bert UW Maesgewoon hoogleraar Verified email at uantwerpen.be Cited by 9976 |
[HTML][HTML] A comprehensive overview of directing groups applied in metal-catalysed C–H functionalisation chemistry
… After that he spent two year as a postdoc in the Maes group in Antwerp (BE), mostly
exploring aerobic oxidation chemistry. Carlo has recently moved to the Eindhoven University of …
exploring aerobic oxidation chemistry. Carlo has recently moved to the Eindhoven University of …
Homogeneous and heterogeneous catalysts for hydrogenation of CO 2 to methanol under mild conditions
… resting state complexes A and B. The formation of … B is formed by coordination of CO possibly
formed from hemiaminal via the known formaldehyde decomposition route. Resting state B …
formed from hemiaminal via the known formaldehyde decomposition route. Resting state B …
Direct α‐functionalization of saturated cyclic amines
…, N Lefevre, L Meerpoel, BUW Maes - … A European Journal, 2012 - Wiley Online Library
… Furthermore, L 31 and its diastereomer L 33 were successfully shown to produce enantioenriched
derivatives 26 a–f from N-isobutyl-2-tributylstannylpyrrolidine (24 b) under conditions …
derivatives 26 a–f from N-isobutyl-2-tributylstannylpyrrolidine (24 b) under conditions …
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test
YF Ghoos, BD Maes, BJ Geypens, G Mys, MI Hiele… - Gastroenterology, 1993 - Elsevier
… (B) The best regression model for these values, omitting two outliers. … increased tl/,b. Full
data on several clinical applications of the breath test are in progress. It is concluded that the [*C]…
data on several clinical applications of the breath test are in progress. It is concluded that the [*C]…
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
…, S Madsen, HH Neumayer, E Cole, B Maes… - The Lancet, 2003 - thelancet.com
Background Renal transplant recipients are at increased risk of premature cardiovascular
disease. Although statins reduce cardiovascular risk in the general population, their efficacy …
disease. Although statins reduce cardiovascular risk in the general population, their efficacy …
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients
…, JM Campos, B Conte‐Devolx, B Maes… - Clinical …, 1998 - Wiley Online Library
… 1b). The male/female ratio was 1/1.35. It was similar for the sporadic and familial forms. …
4b). Patients with normal preoperative CEA levels (P < 0.0004) and whose pre-operative CT had …
4b). Patients with normal preoperative CEA levels (P < 0.0004) and whose pre-operative CT had …
[HTML][HTML] Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
…, B Maes, P Ambühl, A Hartmann, B Staffler… - American Journal of …, 2005 - Elsevier
Renal transplant recipients (RTR) have an increased risk of premature cardiovascular
disease. The ALERT study is the first trial to evaluate the effect of statin therapy on cardiac …
disease. The ALERT study is the first trial to evaluate the effect of statin therapy on cardiac …
Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study
…, D Kuypers, B Maes, B Bammens… - Nephrology Dialysis …, 2004 - academic.oup.com
Background. The natural history of parathyroid function after successful renal transplantation
(RT) and the factors predisposing to persistent hyperparathyroidism (HPT) are not well …
(RT) and the factors predisposing to persistent hyperparathyroidism (HPT) are not well …
[HTML][HTML] Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study
BD Maes, R Oyen, K Claes, P Evenepoel, D Kuypers… - Kidney international, 2004 - Elsevier
… the glycosylation of adhesion molecules in T and B lymphocytes 12., 13., 14., 15.. As such,
MPA selectively inhibits the proliferation of T and B lymphocytes, the production of antibodies, …
MPA selectively inhibits the proliferation of T and B lymphocytes, the production of antibodies, …
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
…, J Floege, G Hetzel, AG Jardine, F Locatelli, BD Maes… - The Lancet, 2017 - thelancet.com
… (B) Absolute mean change in UPCR from baseline in patients receiving 16 mg/day or 8
mg/day TRF-budesonide or placebo for the 9-month treatment phase and 3-month follow-up …
mg/day TRF-budesonide or placebo for the 9-month treatment phase and 3-month follow-up …